Ultragenyx Pharmaceutical (RARE) Receivables - Net (2016 - 2025)
Ultragenyx Pharmaceutical (RARE) has disclosed Receivables - Net for 10 consecutive years, with $158.0 million as the latest value for Q4 2025.
- Quarterly Receivables - Net rose 85.88% to $158.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $158.0 million through Dec 2025, up 85.88% year-over-year, with the annual reading at $158.0 million for FY2025, 85.88% up from the prior year.
- Receivables - Net for Q4 2025 was $158.0 million at Ultragenyx Pharmaceutical, up from $112.5 million in the prior quarter.
- The five-year high for Receivables - Net was $158.0 million in Q4 2025, with the low at $1.6 million in Q1 2025.
- Average Receivables - Net over 5 years is $46.1 million, with a median of $34.2 million recorded in 2022.
- The sharpest move saw Receivables - Net surged 153.11% in 2022, then tumbled 98.11% in 2025.
- Over 5 years, Receivables - Net stood at $20.2 million in 2021, then skyrocketed by 36.14% to $27.5 million in 2022, then skyrocketed by 42.55% to $39.2 million in 2023, then skyrocketed by 116.84% to $85.0 million in 2024, then skyrocketed by 85.88% to $158.0 million in 2025.
- According to Business Quant data, Receivables - Net over the past three periods came in at $158.0 million, $112.5 million, and $2.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.